Impurity Profiling in Active Pharmaceutical Ingredients and Finished Products: Trends, Tools, and Quality Risk Management Approaches

Abstract

Impurity profiling is fundamental to pharmaceutical quality assurance, underpinning the safety, efficacy, and regulatory acceptability of drug substances and finished products. A landmark workshop convened by the American Association of Pharmaceutical Scientists (AAPS) highlighted the need for coordinated scientific and regulatory strategies to identify, monitor, and control impurities throughout drug development. Pharmaceutical impurities—including organic degradation products, inorganic residues, residual solvents, synthetic by-products, genotoxic impurities, and excipient–API interaction products—can compromise drug stability and patient safety if inadequately controlled. Internationally harmonized frameworks such as ICH Q3A/Q3B, ICH Q3C, and ICH M7 provide threshold-based approaches to impurity identification, qualification, and toxicological assessment. Concurrent advances in analytical technology—HPLC, UPLC, LC-MS, GC-MS, ICP-MS, and NMR—have substantially improved trace-level impurity detection, while the integration of Process Analytical Technology (PAT) enables real-time monitoring within a quality-by-design (QbD) framework. Growing attention to extractables and leachables, continuous manufacturing, and predictive toxicology further reflects the increasing complexity of impurity management. This review synthesizes current impurity classification schemes, regulatory expectations, analytical methodologies, and emerging trends, and argues for a unified, multidisciplinary approach to impurity profiling in contemporary pharmaceutical development.